Carroll Financial Associates’s Alaunos Therapeutics TCRT Stock Holding History

Carroll Financial Associates’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$6K	Hold	40	–	–	﹤0.01%	1306
2021 Q3	$10K	Hold	40	–	–	﹤0.01%	1229
2021 Q2	$15K	Hold	40	–	–	﹤0.01%	1174
2021 Q1	$21K	Hold	40	–	–	﹤0.01%	1006
2020 Q4	$15K	Hold	40	–	–	﹤0.01%	1007
2020 Q3	$15K	Hold	40	–	–	﹤0.01%	941
2020 Q2	$19K	Hold	40	–	–	﹤0.01%	871
2020 Q1	$14K	Hold	40	–	–	﹤0.01%	863
2019 Q4	$28K	Hold	40	–	–	﹤0.01%	797
2019 Q3	$25K	Hold	40	–	–	﹤0.01%	765
2019 Q2	$34K	Hold	40	–	–	﹤0.01%	690
2019 Q1	$23K	Hold	40	–	–	﹤0.01%	716
2018 Q4	$13K	Hold	40	–	–	﹤0.01%	785
2018 Q3	$19K	Hold	40	–	–	﹤0.01%	727
2018 Q2	$18K	Hold	40	–	–	﹤0.01%	721
2018 Q1	$23K	Hold	40	–	–	﹤0.01%	637
2017 Q4	$24K	Hold	40	–	–	﹤0.01%	618
2017 Q3	$39K	Hold	40	–	–	﹤0.01%	534
2017 Q2	$37K	Hold	40	–	–	﹤0.01%	556
2017 Q1	$38K	Hold	40	–	–	﹤0.01%	532
2016 Q4	$32K	Hold	40	–	–	﹤0.01%	543
2016 Q3	$33K	Hold	40	–	–	0.01%	549
2016 Q2	$32K	Hold	40	–	–	0.01%	522
2016 Q1	$44K	Buy	+40	New	+$40.9K	0.01%	452
2015 Q1	–	Sell	-20	Closed	-$26K	–	861
2014 Q4	$26K	Buy	+20	New	+$10.6K	0.02%	343

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carroll Financial Associates's TCRT Position: Q4 2021 in Review

Carroll Financial Associates held its Alaunos Therapeutics (TCRT) position steady in Q4 2021 at 40 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Carroll Financial Associates first reported a position in TCRT in Q4 2014 and has held it in 25 quarters since. The position peaked at $44K in Q1 2016. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

Carroll Financial Associates held 40 shares of Alaunos Therapeutics worth $6K as of Q4 2021.
Carroll Financial Associates left its Alaunos Therapeutics share count unchanged in Q4 2021.
Alaunos Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1306 holding.
Carroll Financial Associates first reported a position in Alaunos Therapeutics in Q4 2014 and has held it in 25 quarters since.
Carroll Financial Associates's Alaunos Therapeutics position peaked at $44K in Q1 2016.
165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.